New MHRA Guideline Could Be Global Pharma's Go-To Standard For GxP Data Integrity
Executive Summary
The UK regulator has done a good job of aligning its final data integrity guideline with those of other international bodies, which means global drug companies will not have to balance competing requirements to achieve compliance, says consultancy firm Rammell. However, some aspects of the guideline, such as following a risk-based approach, could pose some challenges.
You may also be interested in...
COVID-19 Vaccine Dosing: Pharma Says Follow The Science As It Gathers Data
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
India Permits Sale Of Some Devices Beyond Licensing Deadline
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Australia Considers Redefining Central Circulatory System To Align With EU
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: